<DOC>
	<DOCNO>NCT00105937</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy OraVescent fentanyl treat breakthrough pain episode cancer patient already opioid tolerant .</brief_summary>
	<brief_title>OraVescent Fentanyl ( OVF ) Treatment Breakthrough Pain Opioid Tolerant Cancer Patients</brief_title>
	<detailed_description>The objective study determine tolerability safety OraVescent fentanyl use long term relieve breakthrough pain opioid tolerant cancer patient .</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1880 year age Average 14 breakthrough pain episode per day Opioid tolerant Histologically document diagnosis malignant solid tumor hematological malignancy Primary breakthrough pain related cancer way Opioid fentanyl intolerance Chronic obstructive pulmonary disease ( COPD ) heart disease Sleep apnea active brain metastasis increase cranial pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Pain</keyword>
</DOC>